Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022

Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022

Precision BioSciences, Inc. DTIL, a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2022 and provide a business update on May 9, 2022. Precision BioSciences also announced that Michael Amoroso, Chief Executive Officer will participate in the H.C. Wainwright Global Investment Conference on May 24, 2022.

Details for the virtual presentation are below:

H.C. Wainwright Global Investment Conference
Date: Tuesday, May 24, 2022
Time: On-demand session available at 7:00 AM ET

A live webcast of the presentation will be accessible on the Company's website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay of the webcast will be available for approximately 30 days.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005330/en/